Gdc-1261

Preclinical

Roche

Gdc-1261 is one of 3 therapeutic programs targeting Advanced Prostate Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Prostate CancerRecruiting

Advanced Prostate CancerPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Advanced Prostate Cancer

#DrugCompanyPhaseTrials

XNW5004

EEvopoint Biosciences Inc.

Phase 2

1 2

HRS-5041

JJiangsu HengRui Medicine Co., Ltd.

Phase 1

1 3

Gdc-1261

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Advanced Prostate Cancer

NCT07567846

Clinical

Trials by Indication[1]

Advanced Prostate Cancer1 trial

A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer

Recruiting· Roche logo

Roche·Preclinical·NCT07567846·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gdc-1261. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Gdc-1261. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Roche

Gdc-1261

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News